New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
Franson will help biopharma clients design a phased approach to inform and execute clinical development plans
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Allam was serving recently as the CEO at Public Investment Fund
Subscribe To Our Newsletter & Stay Updated
